There has been a lot of worry and concern over the past couple of days in respect of some information that has come from another forum.
This information concerned an old PresQuipp bulletin (DROP list) regarding the use of T3.
Unfortunately, because of the name of the bulletin, it has been assumed, wrongly, that T3 is going to be dropped from the prescription list. According to PresQuipp's Bulletin: The PrescQIPP DROP-List (previously called DRugs Of low Priority)1 was first published in 2012 and was an accumulation of medicines that PCTs within the East of England considered as low priority, poor value for money or for which there were safer alternatives. The DROP-List has now been updated and incorporates drugs prescribed across the NHS that are considered low priority and poor value for money and also some of the NICE do not do items, which can be easily measured using prescribing data. It also incorporates drugs which could potentially be provided as self care, with advice and support from the community pharmacists, and discusses the potential to support medicines optimisation for the drugs listed. The DROP-List acronym now represents Drugs to Review for Optimised Prescribing.
In a later (up to date) DROP list (February 2016) liothyronine is mentioned along with the updated BTA Statement, which, as we know, states that some people may need T3 along with their T4. PresQuipp are simply stating the facts - the facts being the information in the latest BTA statement.
Obviously, Thyroid UK is very concerned about how things are going in respect of the prescribing of T3 and this is why we will be discussing the way forward at our Strategic Planning meeting on 30th April. This has been on our agenda to discuss at this meeting for some time along with other projects that we think will help patients with thyroid disease. Thyroid UK is always working behind the scenes to help people with thyroid disease. When we release information, we always try to ensure that it is accurate and up to date.
We will keep you all informed of what was decided at our Strategic Planning Meeting in respect of any campaigns and projects that we decide to do.
Lyn Mynott, CEO, Thyroid UK